Summary
Cryo-Cell International Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Joel A. Schreiber SFI Advisors LLC | 165,300 | $975,270 | $562,020 | -$413,250 | -42.37% |
Cryo-Cell International Inc. (CCEL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cryo-Cell International Inc. ever had a stock split?
Cryo-Cell International Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | David Portnoy CEO | AMEX Exchange | 228895108 CUSIP |
| US Country | 73 Employees | 21 May 2025 Last Dividend | - Last Split | - IPO Date |
Overview
Cryo-Cell International, Inc. specializes in the advanced biotechnology processes of cellular processing and cryogenic storage, particularly focusing on umbilical cord blood stem cells for family use. Since its inception in 1989, the company has been at the forefront of regenerative medicine, offering innovative services for the collection and preservation of these vital stem cells. It targets expectant parents through direct marketing and informational distributions via healthcare professionals such as obstetricians, pediatricians, and childbirth educators, among others. Headquartered in Oldsmar, Florida, Cryo-Cell International is dedicated to advancing medical treatments and therapies by harnessing the potential of mesenchymal stem cells, which show promise in treating a wide array of serious medical conditions.
Products and Services
- Cord Tissue Service
This service offers clients the opportunity to store a section of the umbilical cord tissue, which is abundant in mesenchymal stem cells. Mesenchymal stem cells are pivotal in regenerative medicine, offering potential treatments for a variety of conditions such as heart and kidney diseases, ALS, wound healing, autoimmune diseases, multiple sclerosis, Alzheimer's, and Parkinson's diseases. By preserving these cells, families can access cutting-edge treatments as they become available.
- PrepaCyte CB Processing System
Cryo-Cell manufactures and sells the PrepaCyte CB Processing System, a proprietary technology designed to efficiently process umbilical cord blood stem cells. This system is a testament to the company's commitment to innovation in the field of cryogenic storage and stem cell preservation. By providing a means to process these cells more effectively, Cryo-Cell ensures that the viability and therapeutic potential of the preserved stem cells are maximized for future medical use.
